drug application – Talk Bio

Actionable Insights Powered by AI

Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis

11 months ago talkbio0Tagged Biological Factors, Center for Drug Evaluation, Chronic small plaque psoriasis, Class, drug application, Innovent, Interleukin-23 Subunit p19, Moderate (severity modifier), National Medical Product Administration, Phase III CLEAR-1 Study, picankibart

Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.